618 related articles for article (PubMed ID: 16752693)
21. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
22. Rush immunotherapy with sublingual administration of grass allergen extract.
Feliziani V; Marfisi RM; Parmiani S
Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
[TBL] [Abstract][Full Text] [Related]
23. Sublingual immunotherapy: focus on tablets.
Passalacqua G; Canonica GW
Ann Allergy Asthma Immunol; 2015 Jul; 115(1):4-9. PubMed ID: 26123419
[No Abstract] [Full Text] [Related]
24. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis.
Williams A; Henzgen M; Rajakulasingam K
Eur Ann Allergy Clin Immunol; 2007 Apr; 39(4):123-6. PubMed ID: 17523386
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.
Agostinis F; Foglia C; Bruno ME; Falagiani P
Eur Ann Allergy Clin Immunol; 2009 Dec; 41(6):177-80. PubMed ID: 20128231
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, placebo-controlled study of preventive immunotherapy with E.P.D., in the treatment of seasonal allergic disease.
Di Stanislao C; Di Berardino L; Bianchi I; Bologna G
Allerg Immunol (Paris); 1997 Feb; 29(2):39-42. PubMed ID: 9084819
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.
Tahamiler R; Saritzali G; Canakcioglu S
Laryngoscope; 2007 Jun; 117(6):965-9. PubMed ID: 17545861
[TBL] [Abstract][Full Text] [Related]
29. [Apropos of sublingual specific immunotherapy].
Sabbah A
Allerg Immunol (Paris); 1998 Apr; 30(4):97-8. PubMed ID: 9631689
[No Abstract] [Full Text] [Related]
30. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
32. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
33. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
34. Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients.
Troise C; Bignardi D; Modena P; Pissacroia C; Di Berardino F
Allerg Immunol (Paris); 2000 Jun; 32(6):246-9. PubMed ID: 10971859
[TBL] [Abstract][Full Text] [Related]
35. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
36. Sublingual immunotherapy for allergic rhinitis.
Wilson DR; Torres LI; Durham SR
Cochrane Database Syst Rev; 2003; (2):CD002893. PubMed ID: 12804442
[TBL] [Abstract][Full Text] [Related]
37. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
38. Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis.
Senna GE; Andri G; Dama AR; Falagiani P; Andri L
Allergol Immunopathol (Madr); 2000; 28(4):238-42. PubMed ID: 11022271
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML; Bruno ME; Falagiani P; Riva G
Allergol Immunopathol (Madr); 2006; 34(5):194-8. PubMed ID: 17064648
[TBL] [Abstract][Full Text] [Related]
40. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
